 |
| |
| Jan-07-20 | Initiated |
RBC Capital Mkts |
Outperform |
$46 |
|
| Oct-17-19 | Resumed |
BofA/Merrill |
Neutral |
$37 |
|
| Jul-30-19 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
$48 → $40 |
|
| Jul-30-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Jun-04-19 | Resumed |
Morgan Stanley |
Overweight |
$48 |
|
| Feb-20-19 | Resumed |
Citigroup |
Neutral |
$41 |
|
| Jan-31-19 | Upgrade |
Credit Suisse |
Neutral → Outperform |
|
|
| Jan-31-19 | Upgrade |
Argus |
Hold → Buy |
|
|
| Jan-23-19 | Downgrade |
UBS |
Buy → Neutral |
|
|
| Dec-11-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Nov-01-18 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
|
|
| Jun-08-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$45 |
|
| Apr-05-18 | Downgrade |
Barclays |
Overweight → Equal Weight |
$41 → $38 |
|
| Jan-29-18 | Reiterated |
SunTrust |
Hold |
$33 → $40 |
|
| Sep-20-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Jul-20-17 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| May-16-17 | Downgrade |
Citigroup |
Neutral → Sell |
|
|
| Dec-02-16 | Initiated |
Guggenheim |
Neutral |
|
|
| Nov-02-16 | Downgrade |
Argus |
Buy → Hold |
|
|
| Oct-13-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
|
|
| Jan-25-20 12:56PM | The Dow is about to face its stiffest test in years MarketWatch |
| Jan-24-20 03:16PM | Dow Inc., Merck share losses contribute to Dow's 133-point drop MarketWatch |
| 11:05AM | What Lies Ahead for Healthcare ETFs in Q4 Earnings? Zacks |
| 10:45AM | Dow Inc., Pfizer share losses lead Dow's 29-point drop MarketWatch |
| 09:54AM | Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU Zacks |
| 09:31AM | Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings? Zacks |
| Jan-23-20 06:00PM | Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments GuruFocus.com |
| 12:13PM | Drug giant taps U of L for first-of-its kind research center American City Business Journals |
| 10:00AM | Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults Business Wire |
| 09:12AM | The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly Zacks |
| 08:46AM | Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards? Zacks |
| 08:13AM | Primary Drivers of the Chinese Economy Investopedia |
| 06:45AM | Pfizers Greenstone and Digital Mens Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate) Business Wire |
| Jan-22-20 05:45PM | Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks |
| 12:41PM | Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP Zacks |
| 09:22AM | Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review Zacks |
| Jan-21-20 08:00AM | Pharma firms not making enough progress against superbugs - report Reuters |
| Jan-20-20 09:03AM | AstraZeneca Announces Positive FDA Updates on Cancer Drugs Zacks |
| Jan-17-20 05:40PM | Pharma and Biotech Arent Worried About Democratic Candidates Attacks Against Drugmakers Barrons.com |
| 07:47AM | Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction Zacks |
| 06:30AM | Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace |
| Jan-16-20 10:32AM | US Indexes Close Higher Wednesday With China Trade Deal Signing GuruFocus.com |
| 08:52AM | Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA Zacks |
| 04:08AM | Glaxo, Pfizer Executives Out of Step on Consumer Units Future Bloomberg |
| 03:01AM | Influencers Transcript: Robert F. Kennedy, Jr., January 16, 2020 Yahoo Finance |
| Jan-15-20 11:00PM | Hedge fund veteran looks to cash in on biotech boom Financial Times |
| 10:48AM | UnitedHealth, Pfizer share gains lead Dow's 150-point climb MarketWatch |
| 10:18AM | Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins Zacks |
| 09:47AM | Dow's 75-point climb led by gains in UnitedHealth, Pfizer stocks MarketWatch |
| 09:07AM | Is Pfizer Inc. (NYSE:PFE) Trading At A 49% Discount? Simply Wall St. |
| 08:00AM | 3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio Zacks |
| 03:08AM | Pfizer Eyes IPO of Glaxo Consumer Venture in 3 to 4 Years Bloomberg |
| Jan-14-20 04:21PM | Dow Jones Today: JPMorgan Gives Dow a Lift as Stocks Falter Near Highs InvestorPlace |
| 01:04PM | Pharmacia Corporation (Old Monsanto) -- Moody's announces completion of a periodic review of ratings of Pfizer Inc. Moody's |
| 12:38PM | Charting a bullish 2020 start: S&P 500 extends break to record territory MarketWatch |
| 11:12AM | JPMorgan Chase, Walgreens Boots share gains contribute to Dow's nearly 75-point climb MarketWatch |
| 11:00AM | 7 Dividend ETFs That Offer Growth in 2020 Zacks |
| 09:55AM | Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M Zacks |
| 08:30AM | Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets PR Newswire |
| Jan-13-20 05:45PM | Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks |
| 01:31PM | Top Pharmaceutical Stocks for Q1 2020 Investopedia |
| 11:30AM | Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year? Zacks |
| 10:26AM | Glaxo Files Marketing Application for Fostemsavir in Europe Zacks |
| 09:46AM | In time for biotech's biggest conference, Union Square costs climb American City Business Journals |
| 09:14AM | Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks |
| 08:46AM | Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB Benzinga |
| 07:51AM | Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments MarketWatch |
| 07:30AM | Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimers Disease and Parkinsons Disease from Pfizer Inc. GlobeNewswire |
| 06:00AM | Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizers Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate GlobeNewswire |
| Jan-10-20 04:33PM | Eli Lilly Made a Deal for Dermira. The Biotechs Stock Price Shows Investors Expect More. Barrons.com |
| 04:30PM | Dow Jones Today: Stocks Pinched by Jobs Disappointment InvestorPlace |
| 03:56PM | Stock Market Gives Back Early Gains After Weakish Jobs Data; These Chinese Growth Stocks Continue To Rise Investor's Business Daily |
| 03:43PM | California may become first state to sell its own prescription drugs Yahoo Finance Video |
| 02:22PM | Pfizer Offers a Strong Combination of Growth and Income GuruFocus.com |
| 01:34PM | Dogs of the Dow 2020: 10 Dividend Stocks to Watch Kiplinger |
| 10:59AM | All Bets Are Off for Amarin Stock InvestorPlace |
| Jan-09-20 01:31PM | Pfizer Stock Has No Momentum in Its Business or on the Charts InvestorPlace |
| 10:05AM | Viatris Will Be the New Kid in Generic Drugs. Dont Expect the Stock to Surge, Analyst Says. Barrons.com |
| 09:55AM | Waltham's Amag Pharma replacing CEO, cutting two products American City Business Journals |
| 08:43AM | Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer Zacks |
| 08:00AM | eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types GlobeNewswire |
| 05:00AM | Top Picks 2020- Pfizer PFE MoneyShow |
| Jan-08-20 05:53PM | Among Top 5 Pharma Companies, Pfizer Was the Worst Performer in 2019 GuruFocus.com |
| 08:13AM | 3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020 Zacks |
| Jan-07-20 03:49PM | 5 Top Stock Trades for Wednesday: MU, SQ, WMT InvestorPlace |
| 11:00AM | Top Health Care Stocks for January 2020 Investopedia |
| 10:06AM | Urbem's 'Quality Strategy' Series: The Installed Base GuruFocus.com |
| 10:02AM | Merck's Keytruda Misses One of Two Goals in Lung Cancer Study Zacks |
| 10:00AM | Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire |
| 09:42AM | Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study Zacks |
| Jan-06-20 05:45PM | Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks |
| 03:14PM | Dogs of the Dow 2020: 10 Dividend Stocks to Watch Kiplinger |
| 03:02PM | Md. biotech outlines path for blood cancer drug, including in China American City Business Journals |
| 01:52PM | New antibiotics struggle to generate sales, pharma companies hurt Yahoo Finance Video |
| 09:00AM | Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily |
| 07:00AM | BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma PR Newswire |
| Jan-05-20 04:52PM | The Sectors We Try to Avoid and Why GuruFocus.com |
| Jan-04-20 07:30PM | These 2 stocks dominated S&P 500 returns in 2019 and the decade MarketWatch |
| 07:30AM | Pfizer Bought a Penny Biotech Stock Just Before It Doubled Barrons.com |
| Jan-03-20 04:25PM | Dow Jones Today: Geopolitical Tensions Lead to a Tense Day for Stocks InvestorPlace |
| 04:15PM | Dow Jones Recovers After 345-Point Drop; Defense Stocks Soar As Facebook, Alphabet Hit New Highs Investor's Business Daily |
| 01:38PM | After Lackluster 2019, Pfizer Stock Could Rebound in 2020 InvestorPlace |
| 10:04AM | Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks |
| 09:58AM | Horizon Therapeutics' Stock Up in a Year on Pipeline Progress Zacks |
| 09:19AM | Glaxo (GSK) Shares Continue to Witness Upside: Here's Why Zacks |
| 09:00AM | AbbVie Stock Is Poised To Become A Top Pharma But Should You Buy It? Investor's Business Daily |
| 08:20AM | The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential Zacks |
| 01:15AM | Pfizer and other drugmakers start 2020 with price rises Financial Times |
| Jan-02-20 11:23AM | Top Stock Reports for Pfizer, BP & Fidelity National Information Services Zacks |
| 10:08AM | Drug-Price Increases Show Business as Usual Despite Public Pressure Barrons.com |
| 09:37AM | 3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020 Zacks |
| 08:11AM | Dow Jones 3 Stock Market Losers Start 2020 With a Hangover TheStreet.com |
| 07:48AM | The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon, Chevron, Pfizer and 3M Zacks |
| Dec-31-19 05:45PM | Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know Zacks |
| 04:20PM | Here Are The Top 5 Dow Jones Laggards This Year And Boeing Isn't The Worst Investor's Business Daily |
| 04:02PM | Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs Reuters |
| 03:59PM | Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs Reuters |
| 12:01PM | Vascepas Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock InvestorPlace |
| 08:55AM | AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer Zacks |
| 08:22AM | Heres Why Amarin Stock Slumped Despite the FDA Approval InvestorPlace |
|
|
|
|
| Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, Merck KGaA, Nektar Therapeutics, Syapse, Inc., eFFECTOR Therapeutics, Inc., and Insilico Medicine, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| PFIZER INC | 10% Owner | Sep 17 | Buy | 18.00 | 50,000 | 900,000 | 4,593,847 | Sep 19 04:19 PM | | Gottlieb Scott | Director | Aug 23 | Buy | 34.72 | 3,000 | 104,160 | 3,000 | Aug 26 09:27 AM | | DAMELIO FRANK A | Executive Vice President | Jul 02 | Sale | 44.09 | 153,184 | 6,753,385 | 337,392 | Jul 03 04:06 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Jun 20 | Sale | 44.00 | 30,000 | 1,320,000 | 80,094 | Jun 21 04:08 PM | | PFIZER INC | 10% Owner | May 13 | Buy | 17.00 | 50,000 | 850,000 | 3,249,973 | May 14 07:34 AM | | MACKENZIE ALEXANDER R | Executive Vice President | Apr 01 | Sale | 42.83 | 15,000 | 642,503 | 110,094 | Apr 02 03:05 PM | | JOHNSON RADY A | Executive Vice President | Mar 15 | Sale | 41.13 | 8,700 | 357,831 | 59,797 | Mar 18 06:37 PM | | Dolsten Mikael | President R&D | Mar 04 | Sale | 43.52 | 49,082 | 2,136,293 | 289,126 | Mar 05 04:54 PM | | ROGERS DAWN | Executive Vice President | Mar 04 | Sale | 42.98 | 15,002 | 644,798 | 14,920 | Mar 05 04:55 PM | | READ IAN C | Executive Chairman | Mar 04 | Sale | 43.29 | 50,788 | 2,198,474 | 1,639,280 | Mar 06 04:03 PM | | READ IAN C | Executive Chairman | Mar 04 | Sale | 43.17 | 530,078 | 22,882,702 | 1,109,202 | Mar 06 04:03 PM | | SUSMAN SALLY | Executive Vice President | Mar 04 | Sale | 43.26 | 8,725 | 377,444 | 172,094 | Mar 06 03:29 PM | | SUSMAN SALLY | Executive Vice President | Mar 04 | Sale | 43.14 | 63,998 | 2,760,698 | 108,096 | Mar 06 03:29 PM | | Dolsten Mikael | President R&D | Mar 01 | Option Exercise | 31.34 | 106,191 | 3,328,057 | 438,679 | Mar 05 04:54 PM | | Dolsten Mikael | President R&D | Mar 01 | Sale | 43.56 | 100,471 | 4,376,852 | 338,208 | Mar 05 04:54 PM | | ROGERS DAWN | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 19,297 | 621,942 | 45,049 | Mar 01 07:47 PM | | SUSMAN SALLY | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 85,763 | 2,764,141 | 228,743 | Mar 01 07:47 PM | | YOUNG JOHN D | Group President | Feb 27 | Option Exercise | 32.23 | 154,374 | 4,975,474 | 441,923 | Mar 01 07:47 PM | | GOETTLER MICHAEL | Group President | Feb 27 | Option Exercise | 32.23 | 30,017 | 967,448 | 48,652 | Mar 01 07:37 PM | | Hwang Angela | Group President | Feb 27 | Option Exercise | 32.23 | 11,792 | 380,056 | 23,635 | Mar 01 07:37 PM | | JOHNSON RADY A | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 30,017 | 967,448 | 81,341 | Mar 01 07:37 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 64,322 | 2,073,098 | 123,145 | Mar 01 07:37 PM | | Lewis-Hall Freda C | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 81,475 | 2,625,939 | 416,278 | Mar 01 07:37 PM | | BOURLA ALBERT | Chief Executive Officer | Feb 27 | Option Exercise | 32.23 | 64,322 | 2,073,098 | 331,982 | Mar 01 07:29 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 27 | Option Exercise | 32.23 | 25,729 | 829,246 | 121,743 | Mar 01 07:29 PM | | DAMELIO FRANK A | Executive Vice President | Feb 27 | Option Exercise | 32.23 | 182,247 | 5,873,821 | 588,177 | Mar 01 07:29 PM | | YOUNG JOHN D | Group President | Feb 23 | Option Exercise | 21.03 | 43,724 | 919,516 | 312,403 | Feb 26 07:45 PM | | JOHNSON RADY A | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 18,004 | 378,624 | 61,182 | Feb 26 07:45 PM | | BOURLA ALBERT | Chief Executive Officer | Feb 23 | Option Exercise | 21.03 | 36,008 | 757,248 | 191,438 | Feb 26 07:45 PM | | Lewis-Hall Freda C | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 87,449 | 1,839,052 | 388,024 | Feb 26 07:45 PM | | DAMELIO FRANK A | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 185,185 | 3,894,441 | 522,576 | Feb 26 07:45 PM | | SUSMAN SALLY | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 97,737 | 2,055,409 | 205,833 | Feb 26 07:46 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 43,724 | 919,516 | 83,781 | Feb 26 07:45 PM | | MACKENZIE ALEXANDER R | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 41,615 | 875,163 | 144,164 | Feb 26 07:10 PM | | CANGIALOSI LORETTA V | Sr. Vice President, Controller | Feb 23 | Option Exercise | 21.03 | 30,864 | 649,070 | 115,139 | Feb 26 07:10 PM | | ROGERS DAWN | Executive Vice President | Feb 23 | Option Exercise | 21.03 | 19,290 | 405,669 | 37,638 | Feb 26 07:10 PM | | GOETTLER MICHAEL | Group President | Feb 23 | Option Exercise | 21.03 | 19,290 | 405,669 | 31,507 | Feb 26 07:11 PM | | LANKLER DOUGLAS M | Executive Vice President | Feb 01 | Sale | 42.75 | 5,000 | 213,750 | 40,057 | Feb 01 07:21 PM | | Dolsten Mikael | President R&D | Jan 31 | Option Exercise | 29.78 | 125,968 | 3,751,425 | 362,051 | Feb 01 07:28 PM | | LANKLER DOUGLAS M | Executive Vice President | Jan 30 | Sale | 41.19 | 38,800 | 1,598,071 | 45,057 | Feb 01 07:21 PM |
|
|
|
|
|
|
